Fitusiran Dosing in Trials Reduced to Lower Blood-clot Risk

Fitusiran Dosing in Trials Reduced to Lower Blood-clot Risk

288439

Fitusiran Dosing in Trials Reduced to Lower Blood-clot Risk

Sanofi has reduced the dosing of its investigational treatment fitusiran in clinical trials to lower the risk of blood clots in people with hemophilia, according to a joint statement representing patient organizations worldwide. In October 2020, the company placed a voluntary dosing hold on its full clinical development program for fitusiran, after reports of non-fatal vascular thrombotic (blood clot-related) events in trial participants. The first two cases were associated with doses of clotting factor concentrates…

You must be logged in to read/download the full post.